JP2017534645A5 - - Google Patents

Download PDF

Info

Publication number
JP2017534645A5
JP2017534645A5 JP2017525016A JP2017525016A JP2017534645A5 JP 2017534645 A5 JP2017534645 A5 JP 2017534645A5 JP 2017525016 A JP2017525016 A JP 2017525016A JP 2017525016 A JP2017525016 A JP 2017525016A JP 2017534645 A5 JP2017534645 A5 JP 2017534645A5
Authority
JP
Japan
Prior art keywords
antibody
seq
amino acid
acid sequence
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017525016A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017534645A (ja
JP6946184B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/075877 external-priority patent/WO2016075036A1/en
Publication of JP2017534645A publication Critical patent/JP2017534645A/ja
Publication of JP2017534645A5 publication Critical patent/JP2017534645A5/ja
Application granted granted Critical
Publication of JP6946184B2 publication Critical patent/JP6946184B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017525016A 2014-11-10 2015-11-06 抗pdgf−b抗体及び使用法 Expired - Fee Related JP6946184B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14192519 2014-11-10
EP14192519.8 2014-11-10
PCT/EP2015/075877 WO2016075036A1 (en) 2014-11-10 2015-11-06 Anti-pdgf-b antibodies and methods of use

Publications (3)

Publication Number Publication Date
JP2017534645A JP2017534645A (ja) 2017-11-24
JP2017534645A5 true JP2017534645A5 (show.php) 2018-12-06
JP6946184B2 JP6946184B2 (ja) 2021-10-06

Family

ID=51947140

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017525016A Expired - Fee Related JP6946184B2 (ja) 2014-11-10 2015-11-06 抗pdgf−b抗体及び使用法

Country Status (15)

Country Link
US (1) US10087246B2 (show.php)
EP (1) EP3218400A1 (show.php)
JP (1) JP6946184B2 (show.php)
KR (1) KR20170082520A (show.php)
CN (1) CN107148429B (show.php)
AR (1) AR102593A1 (show.php)
AU (1) AU2015345322A1 (show.php)
BR (1) BR112017009792A2 (show.php)
CA (1) CA2963723A1 (show.php)
IL (1) IL251286A0 (show.php)
MX (1) MX2017005975A (show.php)
RU (1) RU2017120361A (show.php)
SG (1) SG11201703426PA (show.php)
TW (1) TW201630934A (show.php)
WO (1) WO2016075036A1 (show.php)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2537100T3 (es) 2009-04-07 2015-06-02 Roche Glycart Ag Anticuerpos biespecíficos trivalentes
BR112017009790A2 (pt) 2014-11-10 2017-12-19 Hoffmann La Roche anticorpos direcionados ao anti-ang2 e métodos de uso
JP2017537896A (ja) 2014-11-10 2017-12-21 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 二重特異性抗体及び眼科に使用する方法
EP3218402A1 (en) 2014-11-10 2017-09-20 F. Hoffmann-La Roche AG Anti-il-1beta antibodies and methods of use
WO2016087416A1 (en) 2014-12-03 2016-06-09 F. Hoffmann-La Roche Ag Multispecific antibodies
BR112018001762A2 (pt) * 2015-07-29 2018-09-18 Allergan Inc anticorpos apenas de cadeia pesada para ang-2
EP3959242A4 (en) * 2019-04-24 2023-09-13 Magenta Therapeutics, Inc. ANTRACYCLINE ANTIBODY-DRUG CONJUGATES AND THEIR USES
CN115397850A (zh) 2020-03-30 2022-11-25 豪夫迈·罗氏有限公司 与vegf和pdgf-b结合的抗体及其使用方法
MX2023008691A (es) 2021-01-25 2023-08-01 Regeneron Pharma Anticuerpos anti- pdgf-b y metodos de su uso para tratar la hipertension arterial pulmonar (pah).
WO2025150482A1 (en) * 2024-01-08 2025-07-17 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecules that bind pdgf-b and pdgf-d, and methods of use
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4935343A (en) 1986-08-08 1990-06-19 Syntex (U.S.A.) Inc. Monoclonal antibodies for interleukin-1β
EP1590369B1 (en) 2003-01-24 2016-03-16 Applied Molecular Evolution, Inc. Human il-1 beta antagonists
CN1934255B (zh) * 2003-08-27 2012-07-11 奥普索特克公司 用于治疗眼新血管疾病的组合治疗
US20050282233A1 (en) * 2004-03-05 2005-12-22 Ludwig Institute For Cancer Research Multivalent antibody materials and methods for VEGF/PDGF family of growth factors
DE102004062361A1 (de) * 2004-12-10 2006-06-22 Cocreate Software Gmbh & Co. Kg Verfahren zur Ableitung von technischen Zeichungen aus 3D Modellen mit mindestens zwei kollidierenden 3D Körpern
PL1838733T3 (pl) * 2004-12-21 2012-02-29 Medimmune Ltd Przeciwciała skierowane przeciwko angiopoetynie-2 i ich zastosowania
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
AR080794A1 (es) 2010-03-26 2012-05-09 Hoffmann La Roche Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2
SG11201408196RA (en) 2012-06-28 2015-03-30 Molecular Partners Ag Designed ankyrin repeat proteins binding to platelet-derived growth factor
EA032192B1 (ru) * 2012-07-13 2019-04-30 Роше Гликарт Аг Биспецифическое антитело к vegf/ang-2, нуклеиновая кислота, кодирующая это антитело, вектор, содержащий нуклеиновую кислоту, клетка-хозяин, способ получения биспецифического антитела и содержащая его фармацевтическая композиция
SG11201503637SA (en) * 2012-11-08 2015-06-29 Clearside Biomedical Inc Methods and devices for the treatment of ocular diseases in human subjects
HK1216428A1 (zh) * 2012-11-09 2016-11-11 辉瑞公司 血小板衍生生长因子b之特异性抗体及其组合物和用途
JO3405B1 (ar) * 2013-01-09 2019-10-20 Regeneron Pharma الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها
TWI747803B (zh) 2013-04-29 2021-12-01 瑞士商赫孚孟拉羅股份公司 人類結合fcrn之經修飾抗體及使用方法
MX382848B (es) 2014-01-15 2025-03-13 Hoffmann La Roche Variantes de región fc con propiedades de unión a receptor fc neonatal (fcrn) modificadas y de unión a proteína a mantenidas.
JP2017537896A (ja) 2014-11-10 2017-12-21 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 二重特異性抗体及び眼科に使用する方法
BR112017009790A2 (pt) 2014-11-10 2017-12-19 Hoffmann La Roche anticorpos direcionados ao anti-ang2 e métodos de uso
EP3218402A1 (en) 2014-11-10 2017-09-20 F. Hoffmann-La Roche AG Anti-il-1beta antibodies and methods of use

Similar Documents

Publication Publication Date Title
JP2017534645A5 (show.php)
JP2017534646A5 (show.php)
JP2020062036A5 (show.php)
JP2017534644A5 (show.php)
JP2017537896A5 (show.php)
RU2017120360A (ru) Биспецифические антитела и способы их применения в офтальмологии
HRP20211528T1 (hr) Trispecifični i/ili trovalentni vezujući proteini za prevenciju ili liječenje hiv infekcije
RU2017120358A (ru) Анти-il-1-бета антитела и способы их применения
HRP20191584T1 (hr) Anti-cd79b protutijela i načini uporabe
JP2020511947A5 (show.php)
RU2019134352A (ru) Новые биспецифические антигенсвязывающие молекулы, обладающие способностью специфически связываться с cd40 и fap
RU2017120361A (ru) Антитела к pdgf-b и способы их применения
JP2020500538A5 (show.php)
JP2018537966A5 (show.php)
JP2014511179A5 (show.php)
JP2016512551A5 (show.php)
JP2019536806A5 (show.php)
HRP20200384T1 (hr) Humanizirana anti-tau(ps422) protutijela i načini uporabe
RU2020124153A (ru) Гуманизированные антитела к cd19 человека и способы их применения
JP2017504566A5 (show.php)
JP2011046732A5 (show.php)
FI3484915T3 (fi) Uusia zikavirusepitooppeihin spesifisesti sitoutuvia vasta-aineita ja niiden käyttöjä
RU2018101978A (ru) Антитела против трансферринового рецептора, обладающие индивидуализированной аффинностью
JP2017528476A5 (show.php)
JP2015533795A5 (show.php)